Hematology

Sustained bedside digital guideline use links to shorter pediatric allo-HCT LOS and lower NRM

Single-center three-era cohort showed sustained platform use associated with 14% shorter LOS versus pre-platform (ratio 0.858; p=0.018). Adjusted mean LOS fell from 53.32 to 45.74 days during sustained use without higher ICU admissions or 30-day readmissions. NRM at 24 months was lower in sustained-use (0.116 vs 0.147), with adjusted Fine-Gray SHR signaling benefit after key adjustments. Interpret results as association from an observational single-center study; assess local adoption and confounding before implementation. 1

EASIX independently predicts major bleeding and early death in APL-like AML

Multicenter study found APL-like AML had higher log2-EASIX than other AMLs and strong correlation with thrombomodulin (r=0.80). Within APL-like cases, high log2-EASIX (OR 5.611), overt DIC, and CD56+ blasts were independent major-bleeding risk factors. High-risk patients had higher early-death rates, particularly with standard VEN-HMA induction. A modified VEN-HMA regimen with reduced venetoclax initiation dose improved early outcomes in high-risk patients in a real-world cohort. 2

Landscape analysis: GvHD trials growing more industry-led and targeted, but many fail early

Review of 384 trials showed rising industry sponsorship, more multicenter designs, and a shift toward targeted, biology-driven therapies. Most trials were small, single-group, and response-focused; patient-reported outcomes were rare (6.4%). Trial termination was common (22.9% prematurely halted), limiting actionable long-term results for transplant recipients. Trial designers should prioritize multicenter collaboration, robust endpoints, and strategies to reduce premature stopping. 3